Please note: The information displayed on this page might be outdated.
GentiBio: Operator of a biotherapeutics company intended to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. The company develops engineered regulatory T cells (EngTregs), thus helping clients by successfully restoring immune tolerance and overcoming major limitations in existing regulatory T-cell therapeutics.
Based in...
US - New England
Clinical Stage
Pre-Clinical Stage
Disease Space
Allergy, Autoimmune, Immunotherapy
Biotechnology, Pharmaceuticals
Market Cap
Therapeutic Modalities
Cell Therapy
Boston, MA 02111
United States

Company Participants at Winter Private Company Showcase

Adel Nada
GentiBio, Co-founder, President and CEO
Adel is Co-founder and Chief Executive Officer of GentiBio. Prior to joining GentiBio, Adel was the Chief Medical Officer of Casebia Therapeutics. In the past, Adel has held executive positions in various biotech and pharmaceutical companies, including Vice President at Intellia Therapeutics and Caladrius Biosciences, and various senior positions directing clinical development at Baxter and Abbott. He successfully led translational immunology programs for the past 12 years for experimental and approved therapies, spanning small and large molecules and engineered immune cell products, including Tregs products. Adel received his medical degree from Alexandria University in Egypt and his master’s degree in Clinical Research from the Pharmacology Dept. at Rush University in Chicago where he also held an academic position. Adel completed advanced studies in drug development at UCSF and University of Basel before becoming a Member of the Faculty of Pharmaceutical Medicine in the UK. Prior to joining the industry, Adel trained in surgery and internal medicine and practiced for 10 years in Chicago.
Catherine Thut, PhD
GentiBio, CBO
Cathy is Chief Business Officer for GentiBio. Prior to joining the company, Cathy was the CEO of Makana Therapeutics, a preclinical stage company aimed at alleviating the organ shortage crisis though xenotransplantation, and led the merger of Makana with Recombinetics to combine the company’s xenotransplantation expertise with Recombinetics’ expertise in genetic engineering and swine husbandry. Prior to Makana, Cathy was Executive Director in the Business Development and Licensing group at Novartis Institutes for BioMedical Research (NIBR), where she worked across multiple therapeutic areas and was responsible for negotiating a number of NIBR’s immuno-oncology partnerships. In 2001, she joined Merck Research Laboratories in West Point, PA, to focus on ocular therapeutics and held positions of increasing responsibility including Therapeutic Area Group leader for Ophthalmology Research. Cathy did her graduate and postdoctoral training at U.C. Berkeley and Stanford University Medical School, respectively, and earned her MBA from MIT’s Sloan School of Management.